ChemoCentryx, Inc. announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. Ms. Herron serves as Senior Vice President and Chief Commercial Officer of ADC Therapeutics, which she joined in November 2019 to build its commercial organization and launch its first marketed product.

Before ADC Therapeutics, she was Executive Vice President and Chief Commercial Officer at Immunogen and President and Executive Vice President, Global Commercial, at MorphoSys US. In 2016 and 2017, Ms. Herron led the Commercial organization at Ariad Pharmaceuticals as Executive Vice President and Chief Commercial Officer and prepared the organization to launch its second commercial product. Earlier in her career, she held commercial leadership roles of increasing responsibility with Bristol-Myers Squibb, Novartis Oncology, and SmithKline Beecham Oncology (GlaxoSmithKline).

Ms. Herron holds an MBA from Georgetown University and a BA in Biology and Economics from Lehigh University. Age is 52.